Disease · MONDO_0002038

head and neck carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. head and neck carcinoma. Diseases, record MONDO_0002038. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002038

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: head and neck carcinoma; Open Targets
Open Targets ID: MONDO_0002038; Open Targets
Other names: carcinoma of craniocervical region, carcinoma of head and neck, carcinoma of neck, carcinoma of the head and neck, craniocervical region carcinoma, neck carcinoma; Open Targets
Disease Ontology: DOID:1542; Disease Ontology
NCI Thesaurus: C35850; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 7 of its 23 drugs, from ClinicalTrials.gov; Open Targets

Drugs23

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
CETUXIMAB	CHEMBL1201577	Antibody	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
DOCETAXEL	CHEMBL3545252	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
CELECOXIB	CHEMBL118	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
METHOTREXATE	CHEMBL34259	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	4	4	4	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	3	3	3	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 23

See all 23 drugs

Targets30

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	3	Programmed cell death protein 1 inhibitor	Phase 3	https://conductscience.org/library/genes/5133	Drugs and targets
CD274	Programmed cell death 1 ligand 1	2	Programmed cell death 1 ligand 1 inhibitor	Phase 2	https://conductscience.org/library/genes/29126	Drugs and targets
EGFR	Epidermal growth factor receptor	2	Epidermal growth factor receptor erbB1 inhibitor	Phase 3	https://conductscience.org/library/genes/1956	Drugs and targets
TUBA1A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	2	Tubulin inhibitor	Phase 3	https://conductscience.org/library/genes/203068	Drugs and targets

1 to 10 of 30

See all 30 targets

Trials22

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00265941	Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer	Phase 3	940	2017-12-21	Head and Neck Cancer	CETUXIMAB, CISPLATIN	Its record names the disease	ClinicalTrials.gov
NCT02105636	Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141)	Phase 3	361	2017-01-11	Squamous Cell Carcinoma of the Head and Neck	CETUXIMAB, DOCETAXEL, METHOTREXATE, NIVOLUMAB	Its record names the disease	ClinicalTrials.gov
NCT02454972	Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors	Phase 2	345	2021-11-22	Advanced Solid Tumors	LURBINECTEDIN	Its record names the disease	ClinicalTrials.gov
NCT03625323	Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC	Phase 2	187	2024-12-18	NSCLC, HNSCC	PEMBROLIZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00923481	A Broad Multi-histology Phase II Study of the Multi-Kinase Inhibitor R935788 (Fostamatinib Disodium) in Advanced Colorectal, Non-small Cell Lung, Head and Neck Hepatocellular and Renal Cell Carcinomas, and Pheochromocytoma and Thyroid Tumors (Multi-H...	Phase 2	37	2012-08-29	Head and Neck Neoplasms, Pheochromocytoma, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell	FOSTAMATINIB DISODIUM	Its record names the disease	ClinicalTrials.gov
NCT00736944	Trial of 2 Cycles of Induction Chemo With Abraxane, Cetuximab, Cisplatin, & 5-FU for Advanced Head and Neck Cancer	Phase 2	30	2014-01-07	Squamous Cell Carcinoma of the Head and Neck	CETUXIMAB, CISPLATIN, FLUOROURACIL, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT01233843	Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.	Phase 3	370		Squamous Cell Head and Neck Carcinoma	CETUXIMAB, CISPLATIN, DOCETAXEL, FLUOROURACIL	Its record names the disease	ClinicalTrials.gov
NCT04787042	Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067	Phase 1/2	316		Cancer, Solid Tumor, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Non Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Carcinoma, MSI-High	VEVOCTADEKIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT02740985	A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies	Phase 1	313		Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC), Colorectal Carcinoma (CRC)	IMARADENANT	Its record names the disease	ClinicalTrials.gov
NCT00603759	COX-2 Inhibitor With Concurrent Chemoradiation in Locally Advanced Head & Neck Carcinoma	Phase 3	122		Head and Neck Cancer	CELECOXIB	Its record names the disease	ClinicalTrials.gov

1 to 10 of 22

See all 22 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
RT + Cisplatin vs RT + Cisplatin + Cetuximab: serious adverse events	208 of 447	237 of 444	891	NCT00265941	Trial comparisons
Nivolumab 3mg/kg vs Investigator Choice: deaths from any cause	220 of 240	119 of 121	361	NCT02105636	Trial comparisons
Nivolumab 3mg/kg vs Investigator Choice: serious adverse events	165 of 236	87 of 111	347	NCT02105636	Trial comparisons

Papers from its trials33

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
37410476	RESULT	1	PubMed
30406032	RESULT	1	PubMed
27727066	RESULT	1	PubMed
25752384	RESULT	1	PubMed
25154822	RESULT	1	PubMed
18640496	RESULT	1	PubMed
15860857	RESULT	1	PubMed
42586218	DERIVED	1	PubMed
41343184	DERIVED	1	PubMed
39403626	DERIVED	1	PubMed

1 to 10 of 33

See all 33 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0002038

GET https://conductscience.org/api/diseases/v1/MONDO_0002038/drugs?page=2

API reference For AI assistants